Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Profit After Tax (2016 - 2025)

CorMedix's Profit After Tax history spans 14 years, with the latest figure at -$38.8 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 1296.27% year-over-year to -$38.8 million; the TTM value through Dec 2025 reached $1.7 million, up 109.48%, while the annual FY2025 figure was $1.7 million, 109.48% up from the prior year.
  • Profit After Tax for Q3 2025 was -$38.8 million at CorMedix, down from $19.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $20.6 million in Q1 2025 and bottomed at -$38.8 million in Q3 2025.
  • The 5-year median for Profit After Tax is -$7.7 million (2021), against an average of -$5.9 million.
  • The largest YoY upside for Profit After Tax was 242.71% in 2025 against a maximum downside of 1296.27% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$7.8 million in 2021, then decreased by 5.34% to -$8.2 million in 2022, then decreased by 18.21% to -$9.7 million in 2023, then surged by 238.78% to $13.5 million in 2024, then crashed by 387.96% to -$38.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Profit After Tax are -$38.8 million (Q3 2025), $19.8 million (Q2 2025), and $20.6 million (Q1 2025).